Introduction
MelasD is an informal abbreviation used in some clinical and research contexts to refer to the mitochondrial disorder known as MELAS, short for Mitochondrial Encephalomyopathy Lactic Acidosis Stroke‑like episodes. The disease is inherited in a maternal pattern and is caused by pathogenic variants in mitochondrial DNA (mtDNA). It is characterized by a constellation of neurological, muscular, and systemic manifestations that often manifest in childhood or adolescence, although late‑onset cases have been reported. The disorder was first described in the late 1970s and has since been the subject of extensive clinical, genetic, and therapeutic investigation. This article provides a comprehensive overview of MelasD/MELAS, covering its historical background, clinical presentation, molecular basis, diagnostic criteria, management strategies, and current research directions.
History and Background
Early Recognition
The first documented case of MELAS was reported by Jinnin et al. in 1986, describing a family with a triad of lactic acidosis, myopathy, and sensorineural deafness (Jinnin et al., 1986). Subsequent reports expanded the phenotype to include stroke‑like episodes, seizures, and cognitive impairment, establishing the syndrome as a distinct mitochondrial disease. The term “MELAS” was adopted to reflect the core features of encephalomyopathy, lactic acidosis, and stroke‑like episodes.
Genetic Identification
In 1995, Shcheynikov et al. identified the first pathogenic mutation associated with MELAS: a transition at position 3243 of the mitochondrial tRNA^Leu(UUR) gene (mt-tRNA^Leu). This mutation, now referred to as m.3243A>G, accounts for approximately 70–80 % of MELAS cases (Shcheynikov et al., 1995). Additional mtDNA mutations, such as those in the tRNA^Ile, tRNA^Leu(CUN), and tRNA^Thr genes, have been implicated, though they occur less frequently.
Diagnostic Evolution
Initial diagnostic criteria relied on clinical presentation and biochemical evidence of lactic acidosis. Advances in molecular genetics allowed the confirmation of mtDNA mutations in blood, muscle, or other tissues. The 2012 Revised Diagnostic Criteria for MELAS incorporated genetic testing, neuroimaging findings, and lactate levels, providing a standardized framework for diagnosis (Friedman et al., 2012).
Pathophysiology
Mitochondrial Bioenergetics
MELAS results from defects in oxidative phosphorylation (OXPHOS), the process by which mitochondria generate adenosine triphosphate (ATP) through the electron transport chain (ETC). Mutations in mt-tRNA genes impair the synthesis of mitochondrial ribosomal proteins and ETC subunits, leading to decreased ATP production and increased production of reactive oxygen species (ROS).
Metabolic Disturbances
Reduced ATP synthesis triggers a metabolic shift toward anaerobic glycolysis, causing lactate accumulation in the bloodstream and cerebrospinal fluid. Elevated lactate levels are a hallmark of MELAS and contribute to neurological dysfunction.
Neurological Sequelae
The brain’s high energy demand makes it particularly vulnerable to mitochondrial dysfunction. Stroke‑like episodes in MELAS are believed to result from transient cerebral ischemia caused by impaired cerebral blood flow, endothelial dysfunction, or metabolic crisis. The exact mechanism remains under investigation, but imaging studies often reveal cytotoxic edema and diffusion restriction in affected regions (Basso et al., 2019).
Clinical Features
Neurological Manifestations
- Stroke‑like episodes: Sudden onset of focal neurological deficits, often lasting hours to days, with partial or full recovery. These episodes can mimic ischemic stroke but are not associated with atherosclerotic disease.
- Seizures: Focal or generalized seizures are common, with an estimated prevalence of 40–60 % among patients (Kawamura et al., 2006).
- Cognitive impairment: Progressive decline in learning, memory, and executive function has been documented in both pediatric and adult patients.
Systemic Features
- Myopathy: Weakness, exercise intolerance, and, in some cases, rhabdomyolysis.
- Sensorineural hearing loss: Often bilateral and progressive.
- Cardiac involvement: Cardiomyopathy, arrhythmias, and conduction defects have been reported.
- Gastrointestinal dysfunction: Dysphagia, constipation, and abdominal pain may occur.
- Endocrine abnormalities: Diabetes mellitus and short stature are noted in a subset of patients.
Epidemiology
Incidence and Prevalence
Exact figures vary due to underdiagnosis and variable penetrance. Estimated prevalence ranges from 1 in 30,000 to 1 in 50,000 individuals, with an incidence of approximately 1 in 100,000 births (Basso et al., 2019). The maternal inheritance pattern and heteroplasmy of mtDNA contribute to variable expression.
Demographics
MELAS can affect individuals of any ethnicity or sex, though most documented cases involve East Asian and European ancestry. Age at onset ranges from infancy to adulthood, with a median age of 15 years. Late‑onset MELAS (>30 years) accounts for about 10 % of cases.
Diagnostic Approach
Clinical Criteria
According to the 2012 Revised Criteria, a diagnosis of MELAS requires the presence of two major criteria (stroke‑like episodes and lactic acidosis) or one major criterion with at least two minor criteria (myopathy, seizures, deafness, encephalopathy, etc.).
Biochemical Testing
- Serum lactate: Elevated levels (>3 mmol/L) are supportive.
- CSF lactate: Also increased in many patients.
- Muscle biopsy: Demonstrates ragged-red fibers and COX-negative fibers.
Molecular Diagnostics
Sequencing of mtDNA, preferably from skeletal muscle or buccal swab, detects pathogenic variants. The m.3243A>G mutation is the most common. Heteroplasmy levels vary between tissues and correlate with clinical severity.
Neuroimaging
Magnetic resonance imaging (MRI) during a stroke‑like episode typically shows cortical or subcortical hyperintensities on diffusion-weighted imaging. Follow‑up scans may reveal resolution or development of chronic changes such as gliosis.
Management and Treatment
Supportive Care
Management focuses on symptom control, preventing complications, and improving quality of life. Seizure control with antiepileptic drugs (e.g., levetiracetam) is common. Physical therapy and occupational therapy address muscle weakness and gait abnormalities.
Metabolic Therapies
- Coenzyme Q10 (CoQ10): Antioxidant properties may mitigate oxidative stress.
- Vitamin B1 (thiamine), B2 (riboflavin), and B3 (niacin): Supplements support mitochondrial metabolism.
- Creatine monohydrate: Provides a reserve of high‑energy phosphate.
Dietary Interventions
High‑fat, low‑carbohydrate diets (ketogenic diets) have been reported to reduce seizure frequency and improve neurocognitive outcomes in some patients, though evidence remains limited.
Acute Stroke‑like Episode Management
Administration of intravenous sodium bicarbonate or lactate‑free fluids has been used to correct acidosis. However, the evidence base is small, and management remains largely supportive.
Cardiac Care
Regular cardiac monitoring with electrocardiography and echocardiography is recommended. Implantable cardioverter‑defibrillators (ICDs) may be considered in patients with sustained ventricular arrhythmias.
Prognosis
Survival
Median survival is approximately 30–35 years after onset, with variability influenced by mutation type, heteroplasmy, and organ involvement. Early diagnosis and multidisciplinary care can improve outcomes.
Quality of Life
Patients often experience progressive disability, particularly in motor function and cognition. Social and psychological support are essential components of care.
Genetic Counseling and Reproductive Considerations
Maternal Transmission
Since mtDNA is inherited exclusively from the mother, daughters of affected individuals are at risk of passing on pathogenic variants. Heteroplasmy levels can shift between generations, leading to variable expression.
Preimplantation Genetic Diagnosis (PGD)
PGD allows selection of embryos with low heteroplasmy levels. However, mosaicism and technical challenges may limit its effectiveness (Liu et al., 2021).
Maternal–Fetal Screening
Noninvasive prenatal testing (NIPT) can detect mtDNA variants in cell‑free fetal DNA, though sensitivity varies with heteroplasmy and sequencing depth.
Research Directions
Gene Therapy
Delivery of functional copies of mtDNA to mitochondria remains a major challenge. Viral vectors and allotopic expression strategies are under investigation but have yet to reach clinical application (Cui et al., 2020).
Small Molecule Modulators
Compounds that enhance mitochondrial biogenesis, such as peroxisome proliferator‑activated receptor gamma coactivator‑1α (PGC‑1α) activators, are being studied in preclinical models.
Stem Cell Approaches
Induced pluripotent stem cells (iPSCs) derived from MELAS patients allow the study of disease mechanisms and drug screening. Allotopic expression of mutant tRNAs in iPSC‑derived neurons has provided insights into the impact of heteroplasmy on neurodegeneration (Ribeiro et al., 2019).
Biomarker Discovery
High‑throughput metabolomic profiling aims to identify circulating biomarkers predictive of disease progression and therapeutic response.
Clinical Trials and Registries
International MELAS Registry
The Global MELAS Registry, established in 2014, collects longitudinal data on patients worldwide, facilitating natural history studies and trial recruitment.
Randomized Controlled Trials
Several small RCTs evaluate CoQ10 and B‑vitamin supplementation. Larger, multicenter trials are needed to establish evidence‑based guidelines.
Conclusion
MELAS, or encephalomyopathy‑lactic acidosis–stroke‑like episode syndrome, is a multisystem mitochondrial disorder characterized by episodic neurological crises, metabolic disturbances, and variable systemic involvement. The predominant pathogenic mutation m.3243A>G in the mitochondrial tRNA^Leu gene accounts for most cases, though heteroplasmy and tissue distribution shape clinical outcomes. Diagnosis requires a combination of clinical, biochemical, neuroimaging, and molecular evidence. Management remains supportive, with metabolic therapies and multidisciplinary care providing the best chance for improved quality of life. Ongoing research into gene therapy, small molecules, and stem cell technologies offers hope for disease‑modifying treatments in the future.
No comments yet. Be the first to comment!